Cargando…
Aberrant miRNAs expressed in HER-2 negative breast cancers patient
BACKGROUND: Breast cancer is a highly heterogeneous pathology, exhibiting a number of subtypes commonly associated with a poor outcome. Due to their high stability, microRNAs are often regarded as non-invasive cancer biomarkers, having an expression pattern specific for their ‘cell of origin’. METHO...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196003/ https://www.ncbi.nlm.nih.gov/pubmed/30342533 http://dx.doi.org/10.1186/s13046-018-0920-2 |
_version_ | 1783364494594932736 |
---|---|
author | Braicu, Cornelia Raduly, Lajos Morar-Bolba, Gabriela Cojocneanu, Roxana Jurj, Ancuta Pop, Laura-Ancuta Pileczki, Valentina Ciocan, Cristina Moldovan, Alin Irimie, Alexandru Eniu, Alexandru Achimas-Cadariu, Patriciu Paradiso, Angelo Berindan-Neagoe, Ioana |
author_facet | Braicu, Cornelia Raduly, Lajos Morar-Bolba, Gabriela Cojocneanu, Roxana Jurj, Ancuta Pop, Laura-Ancuta Pileczki, Valentina Ciocan, Cristina Moldovan, Alin Irimie, Alexandru Eniu, Alexandru Achimas-Cadariu, Patriciu Paradiso, Angelo Berindan-Neagoe, Ioana |
author_sort | Braicu, Cornelia |
collection | PubMed |
description | BACKGROUND: Breast cancer is a highly heterogeneous pathology, exhibiting a number of subtypes commonly associated with a poor outcome. Due to their high stability, microRNAs are often regarded as non-invasive cancer biomarkers, having an expression pattern specific for their ‘cell of origin’. METHOD: Triple negative breast cancer (TNBC: ER-, PR-, Her-2-) and double positive breast cancer (DPBC: ER+, PR+, Her-2) miRNA expression patterns were obtained by analysis of the TCGA (The Cancer Genome Atlas) data, followed by PCR-array analysis on plasma samples from 20 TNBC patients, 14 DPBC patients and 11 controls. RESULTS: Three downregulated and nine upregulated miRNAs were obtained from the TNBC analysis. Five overexpressed miRNAs were identified in the DPBC group. Four of the dysregulated miRNAs (miR-10a, miR-125b, miR-210 and miR-489) were common for both groups. The cluster miR-17-92 (miR-17, miR-20a, miR-20b, and miR-93), along with miR-130, miR-22 and miR-29a/c, were found to differentiate between TNBC and DPBC. A panel of five transcripts (miR-10a, miR-125, miR-193b, miR-200b and miR-489) was validated in a new set of plasma samples. The overlapping of TCGA and plasma profiling data revealed miR-200b, miR-200c, miR-210 and miR-29c as common signature. MiR-200b was validated on additional normal and tumor tissue samples. The expression level of this transcript from the TCGA data was correlated with lung and bone metastatic genes. CONCLUSION: The miR-200b presents a great potential for the future advancements in the diagnostic/prognostic and therapeutic approach of TNBC, along with other coding or non-coding transcripts. However, this needs to be further integrated in a regulatory network that acts in conjunction with other markers that affect the patients’ prognosis or response to therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0920-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6196003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61960032018-10-30 Aberrant miRNAs expressed in HER-2 negative breast cancers patient Braicu, Cornelia Raduly, Lajos Morar-Bolba, Gabriela Cojocneanu, Roxana Jurj, Ancuta Pop, Laura-Ancuta Pileczki, Valentina Ciocan, Cristina Moldovan, Alin Irimie, Alexandru Eniu, Alexandru Achimas-Cadariu, Patriciu Paradiso, Angelo Berindan-Neagoe, Ioana J Exp Clin Cancer Res Research BACKGROUND: Breast cancer is a highly heterogeneous pathology, exhibiting a number of subtypes commonly associated with a poor outcome. Due to their high stability, microRNAs are often regarded as non-invasive cancer biomarkers, having an expression pattern specific for their ‘cell of origin’. METHOD: Triple negative breast cancer (TNBC: ER-, PR-, Her-2-) and double positive breast cancer (DPBC: ER+, PR+, Her-2) miRNA expression patterns were obtained by analysis of the TCGA (The Cancer Genome Atlas) data, followed by PCR-array analysis on plasma samples from 20 TNBC patients, 14 DPBC patients and 11 controls. RESULTS: Three downregulated and nine upregulated miRNAs were obtained from the TNBC analysis. Five overexpressed miRNAs were identified in the DPBC group. Four of the dysregulated miRNAs (miR-10a, miR-125b, miR-210 and miR-489) were common for both groups. The cluster miR-17-92 (miR-17, miR-20a, miR-20b, and miR-93), along with miR-130, miR-22 and miR-29a/c, were found to differentiate between TNBC and DPBC. A panel of five transcripts (miR-10a, miR-125, miR-193b, miR-200b and miR-489) was validated in a new set of plasma samples. The overlapping of TCGA and plasma profiling data revealed miR-200b, miR-200c, miR-210 and miR-29c as common signature. MiR-200b was validated on additional normal and tumor tissue samples. The expression level of this transcript from the TCGA data was correlated with lung and bone metastatic genes. CONCLUSION: The miR-200b presents a great potential for the future advancements in the diagnostic/prognostic and therapeutic approach of TNBC, along with other coding or non-coding transcripts. However, this needs to be further integrated in a regulatory network that acts in conjunction with other markers that affect the patients’ prognosis or response to therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0920-2) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-20 /pmc/articles/PMC6196003/ /pubmed/30342533 http://dx.doi.org/10.1186/s13046-018-0920-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Braicu, Cornelia Raduly, Lajos Morar-Bolba, Gabriela Cojocneanu, Roxana Jurj, Ancuta Pop, Laura-Ancuta Pileczki, Valentina Ciocan, Cristina Moldovan, Alin Irimie, Alexandru Eniu, Alexandru Achimas-Cadariu, Patriciu Paradiso, Angelo Berindan-Neagoe, Ioana Aberrant miRNAs expressed in HER-2 negative breast cancers patient |
title | Aberrant miRNAs expressed in HER-2 negative breast cancers patient |
title_full | Aberrant miRNAs expressed in HER-2 negative breast cancers patient |
title_fullStr | Aberrant miRNAs expressed in HER-2 negative breast cancers patient |
title_full_unstemmed | Aberrant miRNAs expressed in HER-2 negative breast cancers patient |
title_short | Aberrant miRNAs expressed in HER-2 negative breast cancers patient |
title_sort | aberrant mirnas expressed in her-2 negative breast cancers patient |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196003/ https://www.ncbi.nlm.nih.gov/pubmed/30342533 http://dx.doi.org/10.1186/s13046-018-0920-2 |
work_keys_str_mv | AT braicucornelia aberrantmirnasexpressedinher2negativebreastcancerspatient AT radulylajos aberrantmirnasexpressedinher2negativebreastcancerspatient AT morarbolbagabriela aberrantmirnasexpressedinher2negativebreastcancerspatient AT cojocneanuroxana aberrantmirnasexpressedinher2negativebreastcancerspatient AT jurjancuta aberrantmirnasexpressedinher2negativebreastcancerspatient AT poplauraancuta aberrantmirnasexpressedinher2negativebreastcancerspatient AT pileczkivalentina aberrantmirnasexpressedinher2negativebreastcancerspatient AT ciocancristina aberrantmirnasexpressedinher2negativebreastcancerspatient AT moldovanalin aberrantmirnasexpressedinher2negativebreastcancerspatient AT irimiealexandru aberrantmirnasexpressedinher2negativebreastcancerspatient AT eniualexandru aberrantmirnasexpressedinher2negativebreastcancerspatient AT achimascadariupatriciu aberrantmirnasexpressedinher2negativebreastcancerspatient AT paradisoangelo aberrantmirnasexpressedinher2negativebreastcancerspatient AT berindanneagoeioana aberrantmirnasexpressedinher2negativebreastcancerspatient |